Guardian Pharmacy Services, Inc. GRDN
41.21
(0.58)
(1.39%)
as of 25 Sep
- Market cap
- $2.7B
- P/E
- 39.2×
Follow GRDN
Insider Buys
alert about insiders buying in the last 12 month
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
40.35 | 38.09 | 44.31 | 39.88 |
P/S ratio |
1.17 | 1.30 | 1.64 | 1.81 | |
P/FCF ratio |
23.90 | 23.26 | 33.93 | 33.23 | |
P/Operating CF |
57.85 | 54.25 | 393.38 | 88.31 | |
P/B ratio |
8.34 | 8.61 | 10.26 | 10.29 | |
Price to Tangible BV |
16.80 | 15.68 | 17.64 | 16.44 | |
EV/Sales |
1.17 | 1.28 | 1.62 | 1.78 | |
EV/EBITDA |
20.28 | 19.47 | 23.49 | 23.90 | |
EV/Operating CF |
18.54 | 18.46 | 26.57 | 26.30 | |
EV/FCF |
23.93 | 22.92 | 33.56 | 32.59 | |
Quick Ratio |
0.88 | 1.04 | 1.10 | 1.26 | |
Current Ratio |
1.22 | 1.38 | 1.46 | 1.65 | |
Net Debt/EBITDA |
(1.64) | (1.80) | (2.74) | (3.40) | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
3.77 | 3.95 | 3.83 | 3.66 | |
Operating CF/Net income |
2.87 | 1.65 | 0.46 | 1.37 | |
Capex/Depreciation |
(0.89) | (0.74) | (0.79) | (0.84) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
15.46% | 13.77% | 17.42% | 16.89% | |
Intangible Assets out of Total Assets |
0.25 | 0.24 | 0.23 | 0.22 | |
Share Based Compensation of Revenue |
1.15% | 0.27% | 0.55% | 0.83% | |
Graham Net Nets |
0.00 | 0.01 | 0.02 | 0.03 | |
Graham Number |
6.78 | 7.88 | 8.38 | 9.80 | |
Earnings Yield |
2.48% | 2.63% | 2.26% | 2.51% | |
Free Cash Flow Yield |
4.18% | 4.30% | 2.95% | 3.01% | |
Revenue per Share |
6.08 | 6.37 | 5.32 | 5.55 | |
Operating CF per Share |
0.45 | 0.55 | 0.10 | 0.47 | |
Capex per Share |
(0.08) | (0.07) | (0.07) | (0.08) | |
Free Cash Flow per Share |
0.37 | 0.49 | 0.02 | 0.40 | |
Cash per Share |
0.59 | 1.05 | 1.02 | 1.42 | |
Shareholders Equity per Share |
3.15 | 3.49 | 3.67 | 4.07 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
3.15 | 3.49 | 3.67 | 4.07 | |
Free Cash Flow |
22.96 | 30.37 | 1.31 | 25.14 | |
Working Capital |
36.33 | 60.93 | 74.64 | 100.63 | |
Capital Expenditures |
(5.21) | (4.23) | (4.75) | (4.89) | |
Net Current Asset Value |
3.74 | 26.90 | 40.67 | 68.73 | |
EV/EBIT |
27.80 | 25.45 | 30.48 | 30.44 | |
Capex to Sales |
0.01 | 0.01 | 0.01 | 0.01 | |
Net Profit Margin |
2.60% | 5.26% | 3.95% | 6.22% | |
Price to Operating Income |
27.76 | 25.82 | 30.82 | 31.04 | |
| Other line items | |||||
Average Receivables |
98.56 | 99.38 | 104.56 | 98.95 | |
Average Payables |
114.27 | 109.31 | 105.11 | 106.60 | |
Average Inventory |
46.54 | 41.95 | 45.30 | 47.30 | |
Average Assets |
369.03 | 366.73 | 380.47 | 399.96 | |
Average Common Equity |
164.70 | 183.95 | 197.82 | 218.66 |
Columns are period end dates